An interventional study of Nudge in Ovarian Cancer, sponsored by Abramson Cancer Center at Penn Medicine. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Abramson Cancer Center at Penn Medicine · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Ovarian Neoplasms by Abramson Cancer Center at Penn Medicine — 4 open to participants now, 4 under way, none of them phase 3. Ovarian Neoplasms · Abramson Cancer Center at Penn Medicine.
Among the 15 studies in Ovarian Neoplasms by Abramson Cancer Center at Penn Medicine, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 with no phase, and was the 14th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →4 of the 15 studies in Ovarian Neoplasms by Abramson Cancer Center at Penn Medicine are open now, in 1 country. Recruiting first, the newest first:
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 30–50 · Women only · Healthy volunteers
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 25+ · Women only · Healthy volunteers
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 1
First in 2007; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 28 across the 10 interventional studies, 50 across the 5 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
Abramson Cancer Center at Penn Medicine is the lead sponsor of 462 studies on the registry; 88 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 14 (42%) have results posted.
3 of the studies in Ovarian Neoplasms by Abramson Cancer Center at Penn Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962059Abramson Cancer Center at Penn MedicineHealthy Volunteers Study | 2027-01-15 |
| NCT07915336Abramson Cancer Center at Penn MedicinePeer Ambassador in Gyn Onc Trials | 2027-09-30 |
| NCT06436248Abramson Cancer Center at Penn MedicinePolygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Ovarian Neoplasms by Abramson Cancer Center at Penn Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to test the effectiveness of clinician nudges on referrals to gynecologic oncology in patients with suspected ovarian cancer.
The primary outcome will be whether or not patients were referred to gynecologic oncology within 14 days of their abnormal imaging results. Secondary and exploratory outcomes are whether the gynecologic visit occurred within 60 days of abnormal imaging and the time from abnormal imaging results to gynecologic oncology visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
When the clinician who ordered the imaging that led to randomization receives the test results, a pre-checked referral order to gynecologic oncology for surgical evaluation will appear in the EHR alongside a brief educational explanation. This will constitute the opt-out default referral order (Figure 3). Clinicians will have the option to unclick the referral to opt out and will be asked to indicate the reason from a pre-populated list of choices; if they do not opt out, the referral to gynecologic oncology will proceed. Imaging findings and referral will be communicated to the patient in keeping with the clinician's usual practice. In keeping with routine practice, referred patients will be contacted by gynecologic oncology's new patient coordinators within 72 hours and offered an appointment within 2 weeks at their preferred location.
Behavioral: Nudge
Clinicians will receive imaging reports per usual practice (i.e., imaging reports that include O-RADS score with recommendation for gynecologic oncology referral in the report) and can place referral through the usual EHR-based ordering system. If referred, patients will be contacted and scheduled as described above.
When the clinician who ordered the imaging that led to randomization receives the test results, a pre-checked referral order to gynecologic oncology for surgical evaluation will appear in the EHR alongside a brief educational explanation. This will constitute the opt-out default referral order (Figure 3). Clinicians will have the option to unclick the referral to opt out and will be asked to indicate the reason from a pre-populated list of choices; if they do not opt out, the referral to gynecologic oncology will proceed. Imaging findings and referral will be communicated to the patient in keeping with the clinician's usual practice. In keeping with routine practice, referred patients will be contacted by gynecologic oncology's new patient coordinators within 72 hours and offered an appointment within 2 weeks at their preferred location.
Referral Rate
Binary indicator of whether the patient was referred to gynecologic oncology within 14 days of abnormal imaging results.
Time frame: Up to one year
Gynecologic Oncology Visit
Whether or not the gynecologic oncology visit occurred within 60 days of abnormal imaging.
Time frame: Up to one year
Time from imaging to visit
Time from abnormal imaging results to gynecologic oncology visit.
Time frame: Up to one year
Plan to share: Yes — We will share data arising from the proposed project to the extent that it is permissible and consistent with the prevailing data use agreements and controlling IRBs. Data sharing will occur in a timely fashion. Following acceptance for publication of the main findings from the final data set, we will provide for the timely release and sharing of the de-identified data from the cohort study and the qualitative interviews. These data sets will be provided upon written request to all interested investigators. Upon acceptance for publication of the main study findings, we will also share upon written request with interested investigators the code used in analyzing data.
Supporting information: Study protocol, Statistical analysis plan
Access criteria: Beginning 1 year after publication with no end date.
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jul 2028, 35 months after the start.
Of 284 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 35 months is below that.
Counting every sponsor, half of 295 studies reached it within 46 months; a quarter within 23 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abramson Cancer Center at Penn Medicine →